Abstract 2934
Background
MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for the detection of GCM. However, in teratoma neither tissue nor serum/plasma are miR371 positive. miR375 is overexpressed in teratoma tissue, but detectability in blood and its utility is unknown.
Methods
GCM patients (pts) enrolled from 10-2016 to 03-2019 in the GU biobank program at British Columbia Cancer were analyzed for plasma miR371/miR375 expression by RT-PCR and quantified by ΔΔCT method. Spike-in cel-miR-39-3p, miR-451 and miR-30b-5p were used as quality/internal controls. Sensitivity, specificity, PPV, NPV, AUC of the ROC of miR375 in detecting teratoma were analyzed.
Results
miR375 expression was measured in 69 pts of whom 15 (22%) had pathologically confirmed residual teratoma post-chemotherapy, 4 (6%) residual post-chemotherapy mass without teratoma, 8 (11%) no evidence of residual disease post-chemotherapy, 15 (22%) metastatic seminoma and 27 (39%) CSI with no evidence of tumor. miR375 expression was significantly higher in pts with residual teratoma-post chemotherapy than in non-teratoma (p < 0.0001). Concurrent miR371 and miR375 expression was evaluated in 17 pts with metastatic nonseminoma prior to and post-chemotherapy. miR371 correlated with viable GCM and disappeared after chemotherapy in all but one pt (presenting residual choriocarcinoma). Post-chemotherapy miR375 was unchanged or increased from pre-chemotherapy samples in 85% of pts with pathologically confirmed post-chemotherapy teratoma and remained low in 90% of patients with either complete response or non-teratoma after chemotherapy. Sensitivity of miR375 was 93% (95% CI: 68-99), specificity 75% (95% CI: 43-95), NPV 90% (95% CI 95%: 57-98), PPV 82% (CI 95%: 63-93) and the AUC of miR375 in the post-chemotherapy setting was 0.93 (95% CI: 0.83-1.0; p < 0.0001).
Conclusions
miR375 is overexpressed and detectable in the plasma of pts with teratoma while its expression is significantly lower in nonseminoma pts without teratoma or in seminoma. The evaluation of miR371/miR375 may be clinically useful to guide therapeutic decisions (surgery or chemotherapy). Larger studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract